Smoking cessation drugs do not elevate risk of serious neuropsychiatric adverse effects

(University of California - San Diego) Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the US) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news